Newron Pharmaceuticals S.p.A. | Finanzwire

Basculer en Français

8630	Companies
143980	Keywords
79657	Articles
76974	Press releases

Headlines Articles Press releases Newron Pharmaceuticals S.p.A.

Home
Companies
Newron Pharmaceuticals S.p.A.

BRIEF

published on 06/25/2024 at 17:50, 10 months 1 day ago

Newron Pharmaceuticals Highlights 2024 Investor Day in NYC

Investor Day Clinical Trials Schizophrenia Newron Pharmaceuticals Evenamide
PRESS RELEASE

published on 06/25/2024 at 17:45, 10 months 1 day ago

Newron Pharmaceuticals reports on its 2024 Investor Day in New York City
Newron Pharmaceuticals reports on its 2024 Investor Day in New York City, highlighting evenamide's potential in treating treatment-resistant schizophrenia. Leading experts present clinical data and benefits of evenamide

Clinical Data Schizophrenia 2024 Investor Day Newron Pharmaceuticals Evenamide
BRIEF

published on 06/18/2024 at 17:50, 10 months 8 days ago

Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City

Investor Day Clinical Research Schizophrenia Newron Pharmaceuticals Evenamide
PRESS RELEASE

published on 06/18/2024 at 17:45, 10 months 8 days ago

Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City
Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City. Key opinion leaders to review findings on evenamide program for treatment-resistant schizophrenia

Investor Day Neuroscience Schizophrenia Newron Pharmaceuticals Evenamide
BRIEF

published on 06/05/2024 at 17:50, 10 months 21 days ago

Newron Pharmaceuticals to Host 2024 Investor Day in New York City

Investor Day New York City Schizophrenia Newron Pharmaceuticals Evenamide
PRESS RELEASE

published on 06/05/2024 at 17:45, 10 months 21 days ago

Newron Pharmaceuticals will host its 2024 Investor Day on June 25 in New York City
Newron Pharmaceuticals announces 2024 Investor Day in New York City focusing on evenamide for treatment-resistant schizophrenia. Leading experts to present new findings

Schizophrenia 2024 Investor Day Newron Pharmaceuticals Evenamide Neurobiology
BRIEF

published on 05/13/2024 at 07:05, 11 months 14 days ago

Newron Pharmaceuticals Announces Positive Results for Evenamide in Schizophrenia Study

Clinical Study Schizophrenia Newron Pharmaceuticals Evenamide Mental Health Treatment
PRESS RELEASE

published on 05/13/2024 at 07:00, 11 months 14 days ago

Newron reports compelling additional data documenting the efficacy of evenamide in pivotal study 008A in poorly responding schizophrenia patients
Newron Pharmaceuticals S.p.A. presents compelling additional data from study 008A showcasing the efficacy of evenamide in poorly responding schizophrenia patients. Significant multi-domain benefits observed in PANSS and CGI-C ratings

Clinical Trial Study Results Newron Pharmaceuticals Evenamide Schizophrenia Patients
BRIEF

published on 04/30/2024 at 07:05, 11 months 27 days ago

Newron Reports Success in Evenamide Schizophrenia Study

Evenamide Schizophrenia Treatment Treatment-resistant Phase II/III Study Glutamatergic Inhibition
PRESS RELEASE

published on 04/30/2024 at 07:00, 11 months 27 days ago

Newron announces positive top-line results from potentially pivotal Phase II/III study 008A with evenamide in schizophrenia patients
Newron Pharmaceuticals S.p.A. announces positive Phase II/III study results of evenamide in schizophrenia patients, meeting primary and key secondary endpoints with good tolerability

Schizophrenia Newron Pharmaceuticals Evenamide Phase II/III Study Glutamatergic Inhibition

Accesswire

Published on 04/26/2025 at 02:00, 1 day 15 hours ago

Battery X Metals Announces Strategic Agreement to Advance Artificial Intelligence-Driven Exploration of Critical Battery Metals in Nevada, USA
Published on 04/25/2025 at 23:30, 1 day 17 hours ago

AIML Innovations Announces Departure of Tim Daniels from Board of Directors
Published on 04/25/2025 at 23:01, 1 day 18 hours ago

Medicure Reports Financial Results for Quarter and Year Ended December 31, 2024
Published on 04/25/2025 at 23:00, 1 day 18 hours ago

AIML Optimizes Quantum Sciences Acquisition to Drive Growth & Strategic Focus
Published on 04/25/2025 at 22:15, 1 day 19 hours ago

Grande Portage Resources Announces Extension of Expiry Date for Warrants

View all ACCESSWIRE

EQS Group

Published on 04/25/2025 at 22:47, 1 day 18 hours ago

DEAG achieves new revenue level in “transformation year” 2024 – Strategic investments and strong start to the year create basis for future sustainable growth
Published on 04/25/2025 at 20:30, 1 day 20 hours ago

EQS-Adhoc: Nagarro SE: Confirms 2024 guidance and dividend, postpones publication for full-year results
Published on 04/25/2025 at 18:44, 1 day 22 hours ago

Turkiye Garanti Bankasi A.S.: CMB Approval for Bond Issuance to Foreign Markets
Published on 04/25/2025 at 18:31, 1 day 22 hours ago

Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 04/25/2025 at 18:30, 1 day 22 hours ago

Fuller, Smith & Turner PLC: Transaction in own shares

Les Echos

Published on 04/25/2025 at 18:16, 1 day 23 hours ago

PR_Carrefour Brazil_25042025
Published on 04/25/2025 at 18:05, 1 day 23 hours ago

Louis Hachette Group - 2025 First-quarter revenue
Published on 04/25/2025 at 18:00, 1 day 23 hours ago

Availability of the 2024 universal registration document
Published on 04/25/2025 at 18:00, 1 day 23 hours ago

Postponement of the publication of the annual financial statements
Published on 04/25/2025 at 17:45, 1 day 23 hours ago

LANSON-BCC: GENERAL SHAREHOLDERS’ MEETING ON APRIL 25, 2025 - DIVIDEND: €0.90 PER SHARE

View all LES ECHOS COMFI WIRE